<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149420</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736X2201</org_study_id>
    <secondary_id>2013-000250-22</secondary_id>
    <nct_id>NCT02149420</nct_id>
  </id_info>
  <brief_title>PD of VAY736 in Patients With Primary Sjögren's Syndrome</brief_title>
  <acronym>CVAY736X2201</acronym>
  <official_title>A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the safety, tolerability, pharmacokinetics and
      therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were enrolled in 2 sequential cohorts:

      Cohort 1: 6 patients received 3 mg/kg or Placebo (2:1 ratio) Cohort 2: 21 patients received
      10 mg/kg, 3 mg/kg or Placebo (6:1:3 ratio)

      At week 24 the blind was broken to assess continuation in the trial:

        -  If a patient received VAY736 and their B cell recovery was demonstrated at Week 24, then
           patients completed the trial.

        -  If a patient received VAY736 and their B cell recovery was NOT demonstrated at Week 24,
           then patients were followed up until B cell recovery was demonstrated

        -  If a patient received placebo, they were offered the option of receiving open-label
           VAY736 (10 mg/kg) in a separate treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2014</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment was unblinded at an individual patient level at Week 24 to determine their progress in the study (follow-up, open-label VAY736 or End of Study Visit).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Incidence of Adverse Events</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Number of subjects with Adverse Events during the double blind treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form (36) Health Survey (SF-36)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Fatigue Inventory (MFI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - AUCinf</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The area under the serum concentration-time curve from time zero to infinity [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - AUClast</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - CL</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The systemic (or total body) clearance from serum following intravenous administration [volume / time]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - Cmax</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The observed maximum serum concentration following drug administration [mass / volume]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - T1/2</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - Tmax</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The time to reach the maximum concentration after drug administration [time]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 Serum Concentration - Vz</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <description>The volume of distribution during the terminal elimination phase following intravenous administration [volume]. The concentration of VAY736 was measured in the serum.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>VAY736 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAY736 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <arm_group_label>VAY736 10 mg/kg</arm_group_label>
    <arm_group_label>VAY736 3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Fulfilled revised European US consensus criteria for pSS

          -  ESSDAI value ≥ 6

          -  Elevated serum titers at screening of ANA (≥ 1:160)

          -  Seropositive at screening for anti-SSA and/or anti-SSB antibodies

          -  Stimulated whole salivary flow rate at screening of &gt; 0 mL/min

        EXCLUSION CRITERIA:

        - Prior or previous use of (specific dosages and intervals prior to study start may apply):
        B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig
        (abatacept), anti-TNF-α mAb, cyclophosphamide, azathioprine and medications known to cause
        dry mouth.

        Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to
        randomization is allowed

          -  Active or recent history of clinically significant infection

          -  Vaccination within 2 month prior to study

          -  History of primary or secondary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>January 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2019</results_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary Sjögren's syndrome, pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02149420/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02149420/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 27 patients were enrolled and randomized into the study at one site in Germany.</recruitment_details>
      <pre_assignment_details>The patients were enrolled in 2 sequential cohorts:
Cohort 1: Six patients were randomized to receive a single dose iv of VAY736 at a dose of 3mg/kg or placebo at a 2:1 ratio.
Cohort 2: Twenty one patients were randomized to receive a single iv dose of VAY736 at a dose of 10.0 mg/kg or 3.0 mg/kg or placebo at a 6:1:3 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>single dose iv of Placebo (+ Option to receive Open label VAY736 10 mg/kg at Week 24)</description>
        </group>
        <group group_id="P2">
          <title>VAY736 3 mg/kg</title>
          <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
        </group>
        <group group_id="P3">
          <title>VAY736 10 mg/kg</title>
          <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="5">for patients entering open label VAY736 10 mg/kg at Week 24</participants>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PD (Pharmacodynamics) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label VAY736 10 mg/kg Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">Patients received single dose of VAY736 10mg/kg at Week 24.</participants>
                <participants group_id="P2" count="0">Only patients origianally randomized to Placebo were allowed to enter this Period.</participants>
                <participants group_id="P3" count="0">Only patients origianally randomized to Placebo were allowed to enter this Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>single dose iv of Placebo</description>
        </group>
        <group group_id="B2">
          <title>VAY736 3 mg/kg</title>
          <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
        </group>
        <group group_id="B3">
          <title>VAY736 10 mg/kg</title>
          <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="11.29"/>
                    <measurement group_id="B2" value="46.8" spread="8.75"/>
                    <measurement group_id="B3" value="55.3" spread="13.35"/>
                    <measurement group_id="B4" value="50.5" spread="12.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)</title>
        <description>The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O4">
            <title>VAY736 Combined</title>
            <description>Combining VAY736 3mg/kg and VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)</title>
          <description>The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="4.08"/>
                    <measurement group_id="O2" value="14.5" spread="9.44"/>
                    <measurement group_id="O3" value="11.5" spread="4.38"/>
                    <measurement group_id="O4" value="12.5" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="5.29"/>
                    <measurement group_id="O2" value="10.7" spread="7.69"/>
                    <measurement group_id="O3" value="10.0" spread="5.36"/>
                    <measurement group_id="O4" value="10.2" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.98"/>
                    <measurement group_id="O2" value="-3.8" spread="8.66"/>
                    <measurement group_id="O3" value="-1.5" spread="3.00"/>
                    <measurement group_id="O4" value="-2.3" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Per protocol the primary analysis was between placebo and the combined VAY736 groups at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.678</p_value>
            <method>repeated measures Bayesian analysis</method>
            <method_desc>with baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.058</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.007</ci_lower_limit>
            <ci_upper_limit>3.180</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)</title>
        <description>The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)</title>
          <description>The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.967" spread="2.2179"/>
                    <measurement group_id="O2" value="6.049" spread="1.2759"/>
                    <measurement group_id="O3" value="6.235" spread="1.5379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.926" spread="1.5822"/>
                    <measurement group_id="O2" value="6.173" spread="1.4753"/>
                    <measurement group_id="O3" value="4.568" spread="2.5966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.041" spread="1.7805"/>
                    <measurement group_id="O2" value="0.123" spread="1.0120"/>
                    <measurement group_id="O3" value="-1.667" spread="1.8918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form (36) Health Survey (SF-36)</title>
        <description>The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form (36) Health Survey (SF-36)</title>
          <description>The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component score: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.886" spread="6.3905"/>
                    <measurement group_id="O2" value="39.445" spread="4.2857"/>
                    <measurement group_id="O3" value="46.015" spread="9.3533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component score: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.788" spread="8.3513"/>
                    <measurement group_id="O2" value="45.493" spread="7.3060"/>
                    <measurement group_id="O3" value="47.671" spread="9.2804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component score: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.098" spread="7.9084"/>
                    <measurement group_id="O2" value="6.048" spread="4.7189"/>
                    <measurement group_id="O3" value="1.656" spread="5.4113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.913" spread="15.2776"/>
                    <measurement group_id="O2" value="37.517" spread="6.8994"/>
                    <measurement group_id="O3" value="43.628" spread="11.3667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.012" spread="13.2991"/>
                    <measurement group_id="O2" value="40.170" spread="11.9815"/>
                    <measurement group_id="O3" value="46.700" spread="11.3182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component score: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.099" spread="5.3361"/>
                    <measurement group_id="O2" value="2.653" spread="17.1261"/>
                    <measurement group_id="O3" value="3.073" spread="11.5823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multidimensional Fatigue Inventory (MFI)</title>
        <description>The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multidimensional Fatigue Inventory (MFI)</title>
          <description>The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Fatigue: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="4.72"/>
                    <measurement group_id="O2" value="17.0" spread="2.37"/>
                    <measurement group_id="O3" value="15.9" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Fatigue: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="4.84"/>
                    <measurement group_id="O2" value="14.2" spread="6.40"/>
                    <measurement group_id="O3" value="12.4" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Fatigue: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.64"/>
                    <measurement group_id="O2" value="-2.8" spread="5.04"/>
                    <measurement group_id="O3" value="-3.5" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Fatigue: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="4.14"/>
                    <measurement group_id="O2" value="15.7" spread="2.34"/>
                    <measurement group_id="O3" value="14.2" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Fatigue: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="3.99"/>
                    <measurement group_id="O2" value="11.2" spread="5.15"/>
                    <measurement group_id="O3" value="10.4" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Fatigue: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.32"/>
                    <measurement group_id="O2" value="-4.5" spread="6.57"/>
                    <measurement group_id="O3" value="-3.8" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Fatigue: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="4.78"/>
                    <measurement group_id="O2" value="14.3" spread="3.78"/>
                    <measurement group_id="O3" value="13.0" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Fatigue: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="4.12"/>
                    <measurement group_id="O2" value="11.3" spread="4.18"/>
                    <measurement group_id="O3" value="9.8" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Fatigue: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.95"/>
                    <measurement group_id="O2" value="-3.0" spread="6.07"/>
                    <measurement group_id="O3" value="-3.2" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced motivation: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="4.93"/>
                    <measurement group_id="O2" value="12.3" spread="3.93"/>
                    <measurement group_id="O3" value="10.9" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced motivation: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="5.32"/>
                    <measurement group_id="O2" value="10.0" spread="4.52"/>
                    <measurement group_id="O3" value="9.8" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced motivation: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.40"/>
                    <measurement group_id="O2" value="-2.3" spread="4.50"/>
                    <measurement group_id="O3" value="-1.1" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced activity: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="2.86"/>
                    <measurement group_id="O2" value="10.8" spread="1.72"/>
                    <measurement group_id="O3" value="12.2" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced activity: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="3.81"/>
                    <measurement group_id="O2" value="8.7" spread="3.61"/>
                    <measurement group_id="O3" value="9.3" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduced activity: Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.80"/>
                    <measurement group_id="O2" value="-2.2" spread="4.83"/>
                    <measurement group_id="O3" value="-2.9" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</title>
        <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</title>
          <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="17.73"/>
                    <measurement group_id="O2" value="66.2" spread="17.53"/>
                    <measurement group_id="O3" value="65.0" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="23.35"/>
                    <measurement group_id="O2" value="43.0" spread="23.82"/>
                    <measurement group_id="O3" value="48.5" spread="17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="12.21"/>
                    <measurement group_id="O2" value="-23.2" spread="31.10"/>
                    <measurement group_id="O3" value="-16.5" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</title>
        <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>PD analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)</title>
          <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
          <population>PD analysis set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="24.86"/>
                    <measurement group_id="O2" value="67.2" spread="13.69"/>
                    <measurement group_id="O3" value="59.8" spread="24.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="21.57"/>
                    <measurement group_id="O2" value="44.2" spread="22.75"/>
                    <measurement group_id="O3" value="40.8" spread="20.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="17.71"/>
                    <measurement group_id="O2" value="-23.0" spread="25.73"/>
                    <measurement group_id="O3" value="-19.0" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - AUCinf</title>
        <description>The area under the serum concentration-time curve from time zero to infinity [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - AUCinf</title>
          <description>The area under the serum concentration-time curve from time zero to infinity [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>day*ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389" lower_limit="186" upper_limit="457"/>
                    <measurement group_id="O2" value="1140" lower_limit="515" upper_limit="1610"/>
                    <measurement group_id="O3" value="971" lower_limit="849" upper_limit="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - AUClast</title>
        <description>The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - AUClast</title>
          <description>The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass × time / volume]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>day*ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385" lower_limit="184" upper_limit="457"/>
                    <measurement group_id="O2" value="1140" lower_limit="514" upper_limit="1610"/>
                    <measurement group_id="O3" value="971" lower_limit="848" upper_limit="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - CL</title>
        <description>The systemic (or total body) clearance from serum following intravenous administration [volume / time]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - CL</title>
          <description>The systemic (or total body) clearance from serum following intravenous administration [volume / time]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>L/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.594" lower_limit="0.427" upper_limit="0.844"/>
                    <measurement group_id="O2" value="0.584" lower_limit="0.550" upper_limit="1.30"/>
                    <measurement group_id="O3" value="0.686" lower_limit="0.427" upper_limit="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - Cmax</title>
        <description>The observed maximum serum concentration following drug administration [mass / volume]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - Cmax</title>
          <description>The observed maximum serum concentration following drug administration [mass / volume]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="45.4" upper_limit="76.5"/>
                    <measurement group_id="O2" value="213" lower_limit="150" upper_limit="283"/>
                    <measurement group_id="O3" value="205" lower_limit="174" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - T1/2</title>
        <description>Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - T1/2</title>
          <description>Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" lower_limit="6.99" upper_limit="13.8"/>
                    <measurement group_id="O2" value="9.51" lower_limit="5.38" upper_limit="15.2"/>
                    <measurement group_id="O3" value="11.0" lower_limit="4.94" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - Tmax</title>
        <description>The time to reach the maximum concentration after drug administration [time]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - Tmax</title>
          <description>The time to reach the maximum concentration after drug administration [time]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="2.00" upper_limit="2.20"/>
                    <measurement group_id="O2" value="2.03" lower_limit="2.00" upper_limit="2.30"/>
                    <measurement group_id="O3" value="2.10" lower_limit="2.02" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAY736 Serum Concentration - Vz</title>
        <description>The volume of distribution during the terminal elimination phase following intravenous administration [volume]. The concentration of VAY736 was measured in the serum.</description>
        <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O2">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Open Label VAY736</title>
            <description>Open label VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>VAY736 Serum Concentration - Vz</title>
          <description>The volume of distribution during the terminal elimination phase following intravenous administration [volume]. The concentration of VAY736 was measured in the serum.</description>
          <population>PK analysis set</population>
          <units>L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.83" lower_limit="6.55" upper_limit="10.7"/>
                    <measurement group_id="O2" value="8.68" lower_limit="7.15" upper_limit="12.4"/>
                    <measurement group_id="O3" value="10.3" lower_limit="4.93" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Incidence of Adverse Events</title>
        <description>Number of subjects with Adverse Events during the double blind treatment period.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>single dose iv of Placebo</description>
          </group>
          <group group_id="O2">
            <title>VAY736 3 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 3mg/kg</description>
          </group>
          <group group_id="O3">
            <title>VAY736 10 mg/kg</title>
            <description>single dose iv of VAY736 at a dose of 10mg/kg</description>
          </group>
          <group group_id="O4">
            <title>VAY736 Combined</title>
            <description>Combining VAY736 3mg/kg and VAY736 10mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Incidence of Adverse Events</title>
          <description>Number of subjects with Adverse Events during the double blind treatment period.</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with AEs within 24hr of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with AEs post 24hr of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Study drug-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Infusion related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date subject has provided informed consent until end of study (Week 28 or when B cell recovery was demonstrated, up to 3 years).</time_frame>
      <desc>All AEs were reported until week 52. After week 52 only AEs related to VAY736 and AEs related to infection, potential malignant events and neutropenia were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>VAY736 3mg/kg</title>
          <description>VAY736 3mg/kg</description>
        </group>
        <group group_id="E3">
          <title>VAY736 10mg/kg</title>
          <description>VAY736 10mg/kg</description>
        </group>
        <group group_id="E4">
          <title>Open Label VAY736 10mg/kg</title>
          <description>Open label VAY736 10mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Auriculotemporal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Noninfective sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urogenital infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

